NASDAQ: INGNInogen Inc Stock
$7.45+0.00 (+0%)
Updated Mar 14, 2025
INGN Price
$7.45
Fair Value Price
N/A
Market Cap
$197.65M
52 Week Low
$6.14
52 Week High
$13.33
P/E
-4.9x
P/B
1.14x
P/S
0.65x
PEG
N/A
Dividend Yield
N/A
Revenue
$335.71M
Earnings
-$35.89M
Gross Margin
46.1%
Operating Margin
-10.87%
Profit Margin
-10.7%
Debt to Equity
0.7
Operating Cash Flow
$6M
Beta
1.06
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
INGN Overview
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INGN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important INGN news, forecast changes, insider trades & much more!
INGN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INGN is good value based on its book value relative to its share price (1.14x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
INGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INGN due diligence checks available for Premium users.
Valuation
INGN fair value
Fair Value of INGN stock based on Discounted Cash Flow (DCF)
Price
$7.45
Fair Value
-$3.51
Undervalued by
312.39%
INGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.9x
Industry
41.08x
Market
3,446.61x
INGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
3.94x
INGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INGN's financial health
Profit margin
Revenue
$80.1M
Net Income
-$9.8M
Profit Margin
-12.2%
INGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
INGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$296.2M
Liabilities
$122.3M
Debt to equity
0.7
INGN's short-term assets ($185.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INGN's short-term assets ($185.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INGN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$11.5M
Financing
-$260.0k
INGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INGN vs Medical Device Stocks
Inogen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.